key: cord-0779165-1o3z8v1b
authors: Berciano, José
title: Serum and cerebrospinal fluid biomarker profiles in acute SARS-Co-2 associated Guillain-Barré syndrome
date: 2021-09-25
journal: Brain Commun
DOI: 10.1093/braincomms/fcab219
sha: fad8f2c0a5d6fea8d51fab37d866257fbb81376e
doc_id: 779165
cord_uid: 1o3z8v1b

nan

I read with great interest the paper by Paterson and colleagues evaluating serum and cerebrospinal fluid biomarkers in acute SARS-Covid-2-associated neurologic disorders including Guillain-Barré syndrome (GBS) 1 . Concerning GBS, they found that levels of neurofilament light protein (NfL) were elevated in serum, but normal in cerebrospinal fluid (CSF). Wisely the authors state that such finding implies that NfL is released from peripheral nerves into blood, and does not freely pass back into CSF. I wish to offer the pathological basis for this proposal.

In very early GBS (≤ 4 days after onset) the main pathogenic lesion is endoneurial inflammatory oedema predominating in nerve segments with less efficient blood-nerve barrier, including spinal nerves, spinal ganglia, spinal nerves, and pre-terminal and terminal nerve segments 2 . In nerve segments possessing epiperineurium, namely external to subarachnoid angle and particularly in spinal nerves, oedema might be pathogenic by means of increasing endoneurial fluid pressure, which constricts transperineurial microcirculation producing rapid ischemic nerve injury, potential cause of distally accentuated Wallerian-like degeneration. Assuming that the aforementioned increase of serum NfL was detected in early stages of GBS/COVID-19, I would suggest that it is correlated with axonal dysfunction caused by inflammatory oedema in extradural nerve trunks. Conceivably, in the course of the disease extension of axonal changes to spinal nerve roots could account for potential NfL changes in CSF.

Data sharing is not applicable to this article as no new data were created or analysed.

The author reports no competing interests. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57 58 59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 

Serum and cerebrospinal fluid biomarker profiles in acute SARS-CoV-2-associated neurological syndromes

Axonal degeneration in Guillain-Barre syndrome: a reappraisal

Perineurium contributes to axonal damage in acute inflammatory demyelinating polyneuropathy

Spinal nerve involvement in early Guillain-Barré syndrome: a clinico-electrophysiological, ultrasonographic and pathological study